Cargando…
Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion
Transition from hormone-sensitive to hormone-refractory metastatic tumor types poses a major challenge for prostate cancer treatment. Tumor antigens that are differentially expressed during this transition are likely to play important roles in imparting prostate cancer cells with the ability to grow...
Autores principales: | Conrad, Fraser, Zhu, Xiaodong, Zhang, Xin, Chalkley, Robert J., Burlingame, Alma L., Marks, James D., Liu, Bin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796542/ https://www.ncbi.nlm.nih.gov/pubmed/19219419 http://dx.doi.org/10.1007/s00109-009-0446-3 |
Ejemplares similares
-
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992) -
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007) -
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
por: Hillerdal, Victoria, et al.
Publicado: (2015) -
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
por: Ghosn, Marwan, et al.
Publicado: (2015) -
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)